Cornea Collagen Crosslinking (CxL)

The U.S. Food and Drug Administration (FDA) has approved corneal collagen crosslinking (CXL) in patients with progressive keratoconus or corneal ectasia following previous refractive surgery. At this time there is no medical therapy available in the United States to control the progression of keratoconus or corneal ectasia following refractive surgery. Corneal collagen crosslinking using UVA light and riboflavin to strengthen corneal tissue has shown promising success in stabilizing corneal curvature and slowing or stopping the progression of keratoconus and post-refractive ectasia.